AtriCure (ATRC) Research & Development (2010 - 2026)

AtriCure (ATRC) has 17 years of Research & Development data on file, last reported at $24.2 million in Q1 2026.

• Research & Development for Q1 2026 came in at $24.2 million, up 7.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.9 million (up 2.08% YoY), and the FY2025 annual result was $99.2 million, up 3.15% from the prior year.
• Research & Development fell to $24.2 million in Q1 2026 per ATRC's latest filing, from $24.5 million in the prior quarter.
• Over five years, Research & Development peaked at $35.0 million in Q4 2024 and troughed at $13.6 million in Q1 2022.
• A 5-year average of $20.6 million and a median of $20.4 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2025: Research & Development jumped 68.09% in 2024, then fell 29.9% in 2025.
• A 5-year view of Research & Development shows it stood at $13.7 million in 2022, then jumped by 51.27% to $20.8 million in 2023, then jumped by 68.09% to $35.0 million in 2024, then declined by 29.9% to $24.5 million in 2025, then dropped by 1.1% to $24.2 million in 2026.
• Business Quant data shows ATRC's Research & Development at $24.2 million in Q1 2026, $24.5 million in Q4 2025, and $22.9 million in Q3 2025.